<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02832999</url>
  </required_header>
  <id_info>
    <org_study_id>CNO20163</org_study_id>
    <nct_id>NCT02832999</nct_id>
  </id_info>
  <brief_title>Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes</brief_title>
  <acronym>LIRAVIS</acronym>
  <official_title>Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in a Sub Saharan African Population With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yaounde Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Yaounde 1</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Buea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yaounde Central Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single blind randomised controlled clinical trial in uncontrolled type 2 Diabetes
      mellitus patients on oral glucose lowering agents, and naive to incretinomimetic.
      Participants will be randomised in two Arms : arm 1 receiving Liraglutide at 1,2 mg/day and
      arm 2 Vildagliptine at 100mg/day over 14 days. The two arms will be compared for 14-day
      changes in insulin secretion and insulin sensitivity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Incretinomimetics include exogenous Glucagon-Like Peptide analogs (GLP1a) such as
      Liraglutide, and inhibitors of Dipeptidyl peptidase IV (DPP4i) that prolong the half-life of
      endogenous GLP1 such as Vildagliptin. It remains unclear which of the two strategies
      (exogenous GLP1 or prolonging half-life of endogenous GLP1) have better short term effect on
      insulin sensitivity and insulin secretion in people living with type 2 diabetes.

      This study aims to investigate the short-term metabolic effects of a GLP-1 analog Liraglutide
      versus a DPP4i Vildagliptin. It is a randomized, controlled, single-blinded clinical trial.
      Study population consists of uncontrolled type 2 diabetes mellitus patients (HbA1c≥7%) under
      mono or bi oral anti-diabetic therapy, naïve of any incretinomimetic treatment. Participants
      are randomized in 2 arms. The intervention in arm 1 consists of add-on subcutaneous
      Liraglutide at 0.6mg/day for 1 week increased to 1.2mg the second week. In the second arm, it
      consists of oral Vildagliptine at 100mg daily for two weeks. The primary outcome is the
      variation in euglycaemic hyperinsulinaemic clamp-derived insulin sensitivity before
      randomization and the day after intervention, secondary outcomes include 14-day changes in
      insulin secretion during a mixed meal tolarance test, body weight and body composition, and
      an indirect calorimetry measured resting energy expenditure. Changes from baseline to 14 days
      in serum creatinine and alanine amino transferase, C-reactive protein and lipid profile will
      also be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin sentivity</measure>
    <time_frame>2 weeks</time_frame>
    <description>2-week change in clamp-measured insulin sensitivity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>insulin secretion</measure>
    <time_frame>2 weeks</time_frame>
    <description>2-week change in meal test measured insulin secretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid profile</measure>
    <time_frame>2 weeks</time_frame>
    <description>2-week change in fasting serum lipids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body weight</measure>
    <time_frame>2 weeks</time_frame>
    <description>2-week change in body weight</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Renal function</measure>
    <time_frame>2 weeks</time_frame>
    <description>2-week change in serum creatinine</description>
  </other_outcome>
  <other_outcome>
    <measure>Inflammation</measure>
    <time_frame>2 weeks</time_frame>
    <description>2-week change in C-reactive protein</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>sub cutaneous liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily add-on subcutaneous injection of Liraglutide at 0.6mg/day for 1 week increased to 1.2mg the second week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Vildagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once daily oral 100mg of Vildagliptine for two weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sub cutaneous liraglutide</intervention_name>
    <description>Liraglutide 1.2mg/day</description>
    <arm_group_label>sub cutaneous liraglutide</arm_group_label>
    <other_name>Victoza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Vildagliptin</intervention_name>
    <description>Vildagliptin 50mg/day</description>
    <arm_group_label>Oral Vildagliptin</arm_group_label>
    <other_name>Galvus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus known for at least one year

          -  Uncontrolled glycaemic profile with HbA1c ≥ 7% on oral antidiabetic mono or bi-therapy

          -  Naïve of incretinomimetic treatment

          -  Informed consent

        Exclusion Criteria:

          -  Change in antidiabetic treatment less than 3 months prior to inclusion

          -  Pancreatitis

          -  Alanine amino transferase &gt; 3 times the normal values

          -  Pregnant or breastfeeding women

          -  Estimated glomerular filtration rate &lt; 60ml/min

          -  Infection less than 10 days prior to inclusion or during the study

          -  Acute complication of diabetes

          -  Total haemoglobin &lt; 11g/dL in women or &lt; 13g/dL in men

          -  Withdrawal of consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugène Sobngwi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yaounde Central Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Obesity Centre</name>
      <address>
        <city>Yaounde</city>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cameroon</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2016</study_first_submitted>
  <study_first_submitted_qc>July 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yaounde Central Hospital</investigator_affiliation>
    <investigator_full_name>Sobngwi Eugene</investigator_full_name>
    <investigator_title>Professor of Endocrinology and Diabetes</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>GLP-1</keyword>
  <keyword>Insulin secretion</keyword>
  <keyword>insulin sensitivity</keyword>
  <keyword>Africa</keyword>
  <keyword>Liraglutide</keyword>
  <keyword>Vildaglipin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Vildagliptin</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

